Medcity Pivot: What if pancreatic cancer becomes a chronic disease?
The philosophy of cancer treatment is always “no pain, no benefit” and the idea of target pathways and “maximum tolerated doses” is closed. Now, Zeskind and its clinical stage biotech companies are trying to try something new in the field of pancreatic cancer.
Instead of shutting patients down around the clock and then giving their maximum doses to the patient, the company is developing a new approach that will shut down the pathway regularly and then “it’s hard to hit the disease for a certain period of time.” Early clinical outcomes of this approach targeting the mitogen-activated protein kinase (MAPK) pathway are promising.
In season 2 of the Pivot podcast across April to June, we focus on innovation in oncology, starting with the lofty goals of immunity, even if cancer is manageable like a chronic disease.
You can watch the entire video here:
